Get the Stockscreener App
78.11
1.92%
1.47
After Hours:
78.11
Globus Medical Inc stock is traded at $78.11, with a volume of 1.55M.
It is up +1.92% in the last 24 hours and down -3.40% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$76.64
Open:
$76.7
24h Volume:
1.55M
Relative Volume:
0.92
Market Cap:
$10.60B
Revenue:
$3.10B
Net Income/Loss:
$586.71M
P/E Ratio:
18.19
EPS:
4.2937
Net Cash Flow:
$605.57M
1W Performance:
-2.51%
1M Performance:
-3.40%
6M Performance:
-17.32%
1Y Performance:
+35.14%
1-Day Range:
$76.07
$78.79
1-Week Range:
$74.94
$82.04
52-Week Range:
$51.79
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
78.11 | 10.60B | 3.10B | 586.71M | 605.57M | 4.2937 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Needham | Hold → Buy |
| Jan-27-26 | Initiated | TD Cowen | Buy |
| Nov-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-07-25 | Upgrade | Truist | Hold → Buy |
| Oct-28-25 | Resumed | Stifel | Hold |
| May-27-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
GMED stock holds steady on Globus Medical's business profile - ad-hoc-news.de
ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now? - TradingView
Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR - GlobeNewswire Inc.
Globus Medical IncA (NYSE:GMED) Screens Well as a GARP Stock with Strong Growth and Reasonable Valuation - ChartMill
BMO Capital Maintains Globus Medical(GMED.US) With Buy Rating, Cuts Target Price to $94 - Moomoo
Intuitive, Globus, Teleflex named top picks at BMO (ISRG:NASDAQ) - Seeking Alpha
BMO Capital Initiates Globus Medical at Outperform With $94 Price Target - marketscreener.com
Stifel Maintains Globus Medical(GMED.US) With Hold Rating, Cuts Target Price to $80 - Moomoo
A Look at Globus Medical Inc (GMED) After 3.3% Decline -- GF Val - GuruFocus
Globus Medical (GMED) Receives Positive Coverage from BMO Capita - GuruFocus
Stifel cuts Globus Medical stock price target on growth concerns - Investing.com
Stifel cuts Globus Medical stock price target on growth concerns By Investing.com - Investing.com India
Globus Medical (GMED) Rose With Device Stocks, Is It Still 27% Undervalued? - Yahoo Finance
What Globus Medical (GMED)'s Robotics-Focused Institutional Interest Means For Shareholders - Sahm
Globus Medical Inc focuses on spine technologies as investors watch long term growth - ad-hoc-news.de
Earnings call transcript: Globus Medical Q1 2026 beats forecasts, stock dips - Investing.com
Globus Medical (GMED) Secures FDA Clearances As Revenue And R And D Stay Strong - Sahm
Price to earnings forward of Globus Medical, Inc. – NYSE:GMED - TradingView
Enterprise value to revenue forward of Globus Medical, Inc. – NYSE:GMED - TradingView
Globus Medical (NYSE:GMED) Shines in Navellier’s Little Book Growth Stock Screen - ChartMill
Globus Medical Inc (GMED) Shares Fall 5.9% -- What GF Score of 9 - GuruFocus
Globus Medical Drops 7.0% Amid Sector-Wide Selling - AlphaStreet
GMED vs. MDT: Which Medical Stock Has More Upside Potential? - Yahoo Finance
Globus Medical Inc Class A Actuals & Estimates (GETTEX:GM0N) - TradingView
Globus Medical Inc Class A Actuals & Estimates (FWB:GM0N) - TradingView
Globus Medical Inc Class A Actuals & Estimates (HAM:GM0N) - TradingView
Price to sales forward of Globus Medical Inc Class A – TRADEGATE:GM0N - TradingView
Globus Medical (GMED) Stock After 47% One-Year Gain Is There More Room To Run - Yahoo! Finance Canada
Globus Medical Inc Class A Actuals & Estimates (XETR:GM0N) - TradingView
Globus Medical Inc Class A Actuals & Estimates (BMV:GMED) - TradingView
GM0N Forecast — Price Target — Prediction for 2027 - TradingView
Globus Medical Inc Class A Actuals & Estimates (TRADEGATE:GM0N) - TradingView
Globus Medical Inc Class A Actuals & Estimates (NYSE:GMED) - TradingView
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing - Stock Traders Daily
Globus Medical updates guidance after NuVasive merger close, shares react on NASDAQ - Ad-hoc-news.de
Globus Medical Inc Class A Actuals & Estimates (BX:GMED) - TradingView
Globus Medical Inc Class A Actuals & Estimates (DUS:GM0N) - TradingView
Globus Medical Inc Class A Actuals & Estimates (BOATS:GMED) - TradingView
A Look at Globus Medical Inc (GMED) After 3.1% Gain -- GF Value $98.62 vs Price $84.65 - GuruFocus
Globus Medical Inc Class A Actuals & Estimates (BIVA:GMED) - TradingView
GMED Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Globus Medical Inc Class A – BIVA:GMED - TradingView
Enterprise value to EBITDA forward of Globus Medical, Inc. – NYSE:GMED - TradingView
Tranche Update on Globus Medical, Inc.'s Equity Buyback Plan announced on May 15, 2025. - marketscreener.com
Earnings Beat Amid Currency Headwinds Might Change The Case For Investing In Globus Medical (GMED) - Sahm
BTIG Maintains Globus Medical(GMED.US) With Hold Rating - Moomoo
ExcelsiusGPS from Globus Medical Inc.robotic spine platform gains traction in US hospitals - AD HOC NEWS
Globus Medical’s Q1 Beat and FX Pressures Might Change The Case For Investing In GMED - Yahoo Finance
Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains? - Yahoo Finance
Globus Medical (GMED) Stock Could Be 28% Undervalued Despite Recent Share Price Bounce - Sahm
A Quick Look at Today's Ratings for Globus Medical(GMED.US), With a Forecast Between $103 to $120 - Moomoo
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):